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Protein palmitoylation (S-acylation) has emerged as an important player in
a range of cellular processes, and as a result, the palmitoyl-acyltransferase
(PAT) enzymes which mediate this modification have entered into the spot-
light. Palmitoyltransferase ZDHHC5 (ZDHHC5) is among the more
unique members of the PAT family as it is mainly localised to the plasma
membrane and contains an extended cytoplasmic domain with several regu-
latory features. ZDHHC5 plays a vital role in a wide range of processes in
different cell types. In this review, we offer a summary of the functions of
ZDHHC5 in synaptic plasticity, cardiac function, cell adhesion and fatty
acid uptake, among other processes. We also explore recent work has
revealed several mechanisms to control the activity, localisation and func-
tion of ZDHHC5.
Introduction
Post-translational modifications (PTMs) of proteins are
used by organisms to regulate almost every cellular pro-
cess. They can fundamentally alter the physiochemical
properties of individual amino acid residues within pro-
teins to regulate protein structure and function. The
addition of lipids to proteins is a particularly potent
class of PTMs as they make regions of proteins more
hydrophobic and can act as anchors to attach soluble
proteins to cellular membranes as well as pinning intra-
cellular loops of integral membrane proteins to the
membrane to regulate local protein conformations.
There are several types of fatty acid modifications,
including myristoylation, prenylation and S-acylation
(palmitoylation). These three types of modification
vary in the types of lipids that are utilised, the residues
they are attached to and, therefore, the types of bond
used to attach them. As a result, each type confers dif-
ferent properties and are often used as an essential
step in protein processing to target proteins to particu-
lar membranes within the cell to ensure correct protein
localisation which is usually very important for proper
protein function. Protein S-acylation is the addition of
a long-chain fatty acid to the side chain of a cysteine
residue via a thioester bond, thus increasing the
hydrophobicity of the protein. S-acylation is often
referred to as protein palmitoylation; as the saturated
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fatty acid, palmitic acid is the most common lipid
added, although proteins can also be modified with
stearic acid and oleic acid [1,2]. Furthermore, palmitic
acid is not only attached to cysteine residues, but also
be attached to proteins through N-palmitoylation [3]
and O-palmitoylation [4]. As with the addition of
other fatty acids to proteins, palmitoylation is primar-
ily used for membrane anchoring [5], although it has
also been shown to promote protein–protein interac-
tions [6]. It is also important for the modulation of the
activity of certain enzymes through the palmitoylation
of active site cysteine residues [7]. Palmitoylation is
fully reversible, like phosphorylation or acetylation,
and only occurs post-translationally, unlike other fatty
acid modifications to proteins, such as N-myristoyla-
tion, which generally occur co-translationally and are
usually irreversible [8]. The reversible nature of this
modification is important, as cycles of protein palmi-
toylation and depalmitoylation have roles in protein
activation and inactivation in response to external
stimuli or signalling pathways.
Palmitoylation is used by cells to alter protein locali-
sation and regulate membrane trafficking, with the
palmitoylation-mediated cycling of specific GTPase
HRas (RAS) G-proteins between the plasma mem-
brane, the Golgi and the other intracellular mem-
branes in response to external triggers being a classic
example [9]. All RAS isoforms are farnesylated on the
C terminus [10]; however, H-RAS and N-RAS are also
palmitoylated [9]. In this system, depalmitoylation of
the Ras by ABHD17 proteins [11] occurs at the
plasma membrane, leading to the protein being dis-
tributed amongst other intracellular membranes,
before being palmitoylated at the Golgi by the Palmi-
toyltransferase zDHHC9 (DHHC9)-GCP16 palmitoyl-
acyltransferase (PAT) complex [12] and then trafficked
back to the plasma membrane. This palmitoylation-
controlled cycling of RAS regulates the activity and
correct subcellular localisation of this critical signalling
protein; if it is disrupted, it can lead to diseases such
as RAS-driven cancers. This example also highlights
the importance of the reversibility of palmitoylation
and how it can be leveraged by the cells to fine-tune
signalling in specific contexts.
Dysregulated palmitoylation has been implicated in
a range of diseases including various cancers, as men-
tioned above with RAS, [13,14] and diabetes [15]. It is
particularly implicated in neurological disorders such
as Huntington’s disease [16], schizophrenia [17] and
Alzheimer’s disease [18]. As palmitic acid is a saturated
fatty acid and can occur in combination with other
lipid modifications, it is also involved in the partition-
ing of proteins into lipid raft subdomains [19,20] which
can be used to concentrate or cluster proteins involved
in a signalling pathway [21]. Stearic acid is also satu-
rated so will have a similar effect, but oleic acid is
unsaturated, so not all S-acylated proteins will neces-
sarily preferentially partition into lipid raft domains
[22]. Although palmitoylation was discovered over
40 years ago on viral proteins [2], it has only been
within the past decade that the extent of protein
palmitoylation has been uncovered with the develop-
ment of proteomic approaches to study the palmitoy-
lated proteome. This has led to the realisation that
palmitoylation is much more widespread than first
thought, with at least 10% of human genes having a
protein product that is palmitoylated [23].
Palmitoyl-acyltransferase enzymes are a large family
of integral membrane proteins (Fig. 1) with 23 pro-
teins containing the signature DHHC motif in a cys-
teine-rich domain, found in the human genome [24,25].
After the discovery of palmitoylation, it took more
than 20 years to discover and describe the PAT
responsible for the palmitoylation of RAS in Saccha-
romyces cerevisiae, the Palmitoyltransferase erf2/Ras
modification protein ERF4 complex [26], as before this
it was thought that palmitoylation could be a non-en-
zymatic process. It was definitively shown that palmi-
toylation was mainly an enzymatic process by
knockout of most of the PATs present in S. cerevisiae
which led to the loss of the majority of cellular palmi-
toylation [27]. Each PAT has a distinct subcellular dis-
tribution, with the majority of PATs resident at the
Golgi [24]. Due to this over-representation of palmi-
toylating enzymes at the Golgi, it has been suggested
that the Golgi is the major centre of protein palmitoy-
lation within the cell [28]. However, it is important to
point out that the endoplasmic reticulum and the
plasma membrane also have resident PATs. Palmitoyl-
transferase ZDHHC5 (ZDHHC5) is somewhat unu-
sual as a PAT as it is mainly present at the plasma
membrane, although some is present in the endosomal
system. It also has an extended C-terminal tail
(Fig. 1), which contains many PTMs including
phosphorylation and palmitoylation [29,30], with a
PDZ-binding ligand at the extreme C terminus of the
protein, through which it could interact with PDZ
domain-containing substrates and regulators [31].
Regulation of cardiac function by
ZDHHC5
ZDHHC5 has several different roles in many spe-
cialised cell types, including the heart where it is the
most abundant PAT [32]. The phenomenon of massive
endocytosis (MEND), where up to 70% of the cell
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surface is internalised [33] in fibroblasts, is inhibited by
knockdown of ZDHHC5 [34]. In cardiac muscle,
MEND occurs during reoxygenation following oxygen
deprivation which would occur following a heart
attack. The absence of ZDHHC5 reduces the occur-
rence of MEND in the heart and reduces the effects of
reoxygenation injury on the heart [35]. Interestingly,
when ZDHHC5-deficient cardiac cells undergo anoxia,
it increases the plasma membrane localisation of the
Na/Ca transporter Na(+)/Ca(2+)-exchange protein 1
(NCX1) and the sodium pump accessory subunit,
phospholemman. This is an intriguing point as palmi-
toylation is often used to stabilise proteins at the
plasma membrane. It may be that palmitoylation of
these proteins is used as a way to trigger their
endocytosis and that by removing the enzyme that
palmitoylates them it leads to a stabilisation of NCX1
and phospholemman at the plasma membrane. Given
that ZDHHC5 is required for MEND, and that
MEND occurs after oxygen re-introduction following
periods of anoxia and appears to be detrimental to the
recovery of heart muscle cells, targeting ZDHHC5
specifically, or potentially palmitoylation more gener-
ally, could be a way to prevent or reduce the detrimen-
tal effects seen in cardiac muscle after heart attacks.
The triggering of MEND is a multi-step process,
which originates in the mitochondria before a cascade
reaches ZDHHC5 at the plasma membrane whereby
the palmitoylation of plasma membrane proteins













Fig. 1. (A) Membrane topology and known
PTMs of ZDHHC5. PTM data is taken from
the Phosphosite database [71]. (B)
Predicted structure of ZDHHC5 based on
the crystal structure of human DHHC17
created using the SWISS-MODEL platform
[72]. The DHHC characteristic catalytic
tetrad and activating phosphorylation site at
Y91 are labelled. The S-acylated
amphipathic helix just C-terminal to the
fourth transmembrane helix is indicated.
This model is missing most of the C-
terminal tail (present in panel A) which is
predicted to be unstructured.
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fibroblasts, a series of steps occurs that begins with the
opening of mitochondrial pores, causing a large release
of coenzyme A, which rapidly binds fatty acid chains
to form acyl-CoA. The increase in acyl-CoA leads to
palmitoylation of a large number of membrane pro-
teins, presumably by ZDHHC5. The blockage of any
step of this process, such as depleting fatty acids which
will prevent acyl-CoA synthesis or preventing the
opening of mitochondrial pores, inhibits the whole
process which demonstrates that this is a specific cas-
cade and that disruption at any point of it stops
MEND [34].
DHHC5 plamitoylates phospholemman, which inter-
acts with and regulates the cardiac sodium pump [36].
This palmitoylation event inhibits sodium pump but
only when one of the two cytoplasmic cysteine residues
of phospholemman is palmitoylated. Although
ZDHHC5 palmitoylates phospholemman, they do not
form a stable complex [37]. Instead, ZDHHC5 is
brought into proximity of phospholemman through
binding the third intracellular loop of the sodium
pump a-subunit [37]. The interaction between the
sodium pump a-subunit and ZDHHC5 is independent
of the PDZ-binding domain of ZDHHC5 and has
recently been mapped to a region consisting of around
40 amino acids (residues 223–267) which encompasses
an amphipathic helix on the C-terminal side of the
fourth and final transmembrane domain (Fig. 1) [37].
This amphipathic helix contains three cysteine residues
which are palmitoylated [29,30] and forms a binding
site for GOLGA7B, which regulates cell surface
expression of ZDHHC5 [38]. Recently, using a prox-
imity labelling approach, DHHC20 was found to inter-
act with ZDHHC5 and to palmitoylate this
amphipathic helix [37] which regulates the recruitment
of the sodium pump and phospholemman palmitoyla-
tion [37].
Interestingly, treatment of cells with a cell-penetra-
tion peptide containing the sequence from the central
portion of the sodium pump a-subunit binding site on
ZDHHC5 inhibited the endogenous interaction, and
therefore, ZDHHC5 mediated palmitoylation of phos-
pholemman. This represents a novel and exciting phar-
macological route to inhibit a PAT [37]. This
mechanism of substrate recruitment explains to some
extent the presence of an extended disordered cytoplas-
mic tail in ZDHHC5 and might be a mechanism
shared by other PATs with similar C termini.
A role for ZDHHC5 in controlling the force of
heart muscle contractions has been demonstrated by
regulation of b-adrenergic signalling [39]. ZDHHC5
palmitoylates G-proteins associated with the b2-adren-
ergic receptor rapidly after receptor activation. The
kinetics of palmitoylation correlated with the timing of
downstream signalling events which lead to the con-
traction of cardiac muscle cells. Furthermore, receptor
stimulation leads to a rapid increase (< 1 min) in the
palmitoylation of the C-terminal tail of ZDHHC5, a
region known to be important in controlling its locali-
sation in the cells [38] and its lateral motility in the
plasma membrane [39]. These data further establish
ZDHHC5 as a vital regulator of crucial processes in
the heart and highlight how palmitoylation can occur
dynamically in response to receptor stimulation.
Activity-dependent synaptic
palmitoylation by ZDHHC5
ZDHHC5 is also highly expressed in the brain, partic-
ularly in the hippocampus, where it localises to the
postsynaptic density [40]. The generation of a
ZDHHC5-GT (gene trap) mouse revealed some inter-
esting roles for ZDHHC5 in the brain [40]. This muta-
tion had a rate of embryonic lethality of around 50%,
and behavioural testing of these mice showed that they
had defects in fear conditioning, suggesting problems
in their learning and memory. This implicates
ZDHHC5 in various processes at the postsynaptic den-
sity involved with the formation and storage of memo-
ries. ZDHHC5 forms a complex with an important
postsynaptic scaffolding protein PSD-95 [41,42]
through an interaction between one of the PDZ
domains of PSD-95 and the PDZ-binding ligand which
is present at the very C terminus of ZDHHC5 (Fig. 2).
Levels of PSD-95 palmitoylation are not altered in
ZDHHC5 mutant mice. In fact, PSD-95 is palmitoy-
lated by several other PATs; DHHC3, a Golgi-resident
PAT, constitutively palmitoylates PSD-95 [43],
DHHC2 palmitoylates PSD-95 in response to synaptic
activity [44] and DHHC17 mediated palmitoylation of
PSD-95 regulates its clustering in neurons [45].
Although ZDHHC5 does not palmitoylate PSD-95,
several binding partners of PSD-95 are palmitoylated
and may be recruited to ZDHHC5 by PSD-95 as sub-
strates.
At the postsynaptic density, ZDHHC5 also palmi-
toylates d-catenin, an important scaffolding protein, in
response to synaptic activity [46]. At the postsynaptic
density, palmitoylated d-catenin associates with the
adhesion molecule N-cadherin, which regulates activ-
ity-dependent spike remodelling. Also, this palmitoyla-
tion event appears to increase the levels of AMPA
receptor subunits at the postsynaptic density, which
may sensitise the neuron to these signals. Context-de-
pendent fear conditioning in mice increased the levels
of d-catenin palmitoylation, which links both d-catenin
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to learning and memory and reveals a potential mech-
anism underlying the phenotypes of the ZDHHC5-GT
mice [40].
Subsequent work has shed further light on the
mechanism of ZDHHC5-mediated palmitoylation of d-
catenin and the nature of its interaction with PSD-95
[47]. At basal conditions, ZDHHC5 is at the plasma
membrane at the postsynaptic density, while d-catenin
is usually present in the dendritic shafts of neurons
[48]. Therefore, in order for ZDHHC5 to palmitoylate
d-catenin, one or both proteins must move to a shared
location. This is accomplished as follows: ZDHHC5 is
held at the plasma membrane through (a) an interac-
tion with PSD-95, which is mediated by the PDZ-bind-
ing ligand on ZDHHC5, and (b) phosphorylation by
the Src family kinase Fyn. In response to synaptic
activity, ZDHHC5 is de-phosphorylated by STEP61
(Fig. 2) and the loss of phosphorylation causes
ZDHHC5 to be endocytosed and trafficked to the den-
dritic shaft, where it then palmitoylates d-catenin
before both traffic back to the postsynaptic density
allowing the recruitment and stabilisation of AMPA
receptors. ZDHHC5 is endocytosed by the clathrin
endocytosis system and requires the AP2 adaptor com-
plex to bind at a canonical AP2-binding motif in the
C terminus of ZDHHC5. As this AP2-binding motif
contains the Fyn phosphorylation site, phosphoryla-
tion acts either to directly block the interaction with
the AP2 complex or prevents the recognition of the
motif on ZDHHC5 by the AP2 complex. The interac-
tion with PSD-95 is unlikely to be dependent on the
phosphorylation event given that the site of phospho-
rylation is not near the PDZ-binding domain of
ZDHHC5, and the interaction is likely disrupted by
the endocytosis of ZDHHC5. However, it is entirely
possible that the phosphorylation event helps to sta-
bilise the interaction between PSD-95 and ZDHHC5
and does not solely function to prevent association
with the AP2 complex and the clathrin endocytosis
machinery. The discovery that ZDHHC5 is trafficked
away from the plasma membrane to palmitoylate d-
catenin opens up the possibility that ZDHHC5 has
other substrates which are not present at the plasma
membrane but are instead found in the dendritic shaft.
It also demonstrates how important PTMs of the
ZDHHC5 C-terminal tail is to the regulation of
ZDHHC5, and how these PTMs could be significant
in regulating the localisation of ZDHHC5.
A role for ZDHHC5 in neuronal development has
also been established [49]. When neuronal stem cells
are starved of growth factors, a treatment which is
often used to differentiate these cells, ZDHHC5 levels
are rapidly (< 5 min) reduced [49]. This reduction mir-
rored the reduction of a stem cell marker during differ-
entiation and could be reversed over shorter time
points by addition of growth factors. Inhibition of the
ubiquitin-proteasome system was able to reduce the
degradation of ZDHHC5 and stabilisation of FGF
signalling (through EGF or FGF2) prevented
Fig. 2. Schematic of ZDHHC5 localisation and movement at the
postsynaptic density in neurons. Adapted from [47]. (1) In basal
conditions ZDHHC5 is localised to the postsynaptic membrane in
complex with Fyn kinase and PSD-95. (2) Binding of AP2, and
internalisation of ZDHHC5 is prevented by phosphorylation of
ZDHHC5 by Fyn kinase. (3) Increased synaptic activity reduces Fyn
kinase activity and ZDHHC5 phosphorylation. Reduced binding to
Fyn and PSD-95 leads to internalisation of ZDHHC5 by AP2
mediated clathrin endocytosis. (4) After internalisation, ZDHHC5
traffics to dendritic shafts on recycling endosomes where it
palmitoylates d-catenin. (5) ZDHHC5 and d-catenin are then
trafficked together back to the postsynaptic membrane, leading to
structural changes of the synapse.
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ZDHHC5 turnover [49]. These data suggest that
ZDHHC5 is rapidly turned over and that its levels are
tightly regulated in response to extracellular signals.
ZDHHC5 may be especially important to maintain
stem cell pluripotency, and it would be interesting to
track the fate of relevant substrates during differentia-
tion to determine whether the reduction in ZDHHC5
leads to a reduction in either their abundance or cellu-
lar localisation.
ZDHHC5 regulates cell adhesion
A large number of adhesion proteins are palmitoylated
[50,51], in particular, the desmosomal complex, with
six palmitoylated components [52,53]. However, until
recently, the identity of the PAT(s) responsible for
desmosomal protein palmitoylation was unknown.
Several threads of evidence pointed to a regulatory
role of ZDHHC5 for one or more of these proteins.
As ZDHHC5 is present at the plasma membrane, it
would be in the same cellular compartment as desmo-
somal proteins to modify them. Recently, an affinity
purification-mass spectrometry (AP-MS) study
revealed that ZDHHC5-GOLGA7B interacts with the
desmosomal cadherin desmoglein-2 (DSG2), a known
palmitoylated desmosomal protein [38]. ZDHHC5 is
the PAT responsible for palmitoylation of DSG2 [38],
and depletion of ZDHHC5 leads to a mislocalisation
of DSG2 in A431 cells. Depletion of ZDHHC5 also
causes a significant inhibition in the trafficking of
DSG2 back to the plasma membrane after disruption
of desmosomes by calcium switch (calcium depletion
and re-introduction). The localisation of ZDHHC5 is
an important factor in mediating the palmitoylation of
DSG2 as it is less palmitoylated when either ZDHHC5
or DSG2 was not localised to the plasma membrane.
This did contradict the hypothesis put forward in pre-
vious work which suggested that DSG2 is palmitoy-
lated at the Golgi [53]. However, it was subsequently
shown that the majority of DSG2 palmitoylation likely
takes place at the plasma membrane as when DSG2 is
internalised by low calcium conditions and is thus sep-
arated from ZDHHC5 which is still present at the
plasma membrane, palmitoylation of DSG2 is signifi-
cantly reduced [38].
Knockdown of ZDHHC5 resulted in a mislocalisa-
tion of DSG2 [38] which was more severe than has
been seen previously with palmitoylation-deficient
mutants of DSG2 [53] but did more closely match the
phenotype observed when palmitoylation of another
desmosomal protein, plakophilin-3 (PKP3), is pre-
vented [52]. In fact, siRNA-mediated knockdown of
ZDHHC5 causes palmitoylation of PKP3 to be
abolished. This points to the effects seen on the locali-
sation of DSG2 being a combination of the loss of
palmitoylation of both PKP3 and DSG2, and posi-
tions ZDHHC5 as the PAT for several desmosomal
proteins.
As desmosomes are essential for proper cell adhe-
sion and other cell adhesion components were found
as interactors of ZDHHC5 in an AP-MS study, it was
hypothesised that loss of ZDHHC5 could affect more
types of cell adhesion [38]. This was tested by adhesion
assays which showed that loss of ZDHHC5 led to a
reduction in overall cell:cell adhesion, implicating
ZDHHC5 not only in desmosomal protein localisation
but in the wider process of cell adhesion [38]. This
could be due to ZDHHC5 having roles in other cell
adhesion processes as ZDHHC5 interacts with other
cell adhesion proteins, such as the tight junction pro-
tein ZO-1. It would be interesting to investigate further
the potential regulation of other adhesion processes by
ZDHHC5, as it could position ZDHHC5 as a regula-
tor of all of these adhesion complexes.
The reduction in adhesion that is driven by the loss
of ZDHHC5 could have implications in several differ-
ent diseases. Desmosomes and DSG2 and plakophilin,
in particular, have been implicated in the serious heart
condition arrhythmogenic right ventricular cardiomy-
opathy (ARVC) [54]. Mutations in these proteins have
been shown to impair the adhesion of the cardiac mus-
cle, which leads to damage of the cardiac muscle. To
our knowledge, palmitoylation of desmosomal compo-
nents has not been implicated in ARVC to date, but
these recent findings open this up as a possibility and
ZDHHC5, which is enriched in the cardiac muscle and




There are several examples of important roles for
palmitoylation in regulating host–pathogen interac-
tions, and ZDHHC5 is involved in both the protection
of host cells from bacterial invasion and the pathogen-
esis of secreted pathogenic toxins. Many toxins require
cleavage by host proteases, including the anthrax toxin
and aerolysin, a toxin that forms a pore in the plasma
membrane of host cells [55]. The cleavage of these pro-
teins is mediated by the proteins Furin and Proprotein
convertase subtilisin/kexin type 7 (PC7), both of which
are ZDHHC5 substrates [55]. Palmitoylation of these
proteins by ZDHHC5 is required for Furin/PC7 to
partition into lipid microdomains where their proxim-
ity to the anthrax toxin and aerolysin facilitates their
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cleavage [55]. Furthermore, ZDHHC5 also has a role
in the recycling of these proteins to the plasma mem-
brane [55]. This effect is likely to be indirect and
linked to the function of ZDHHC5 in endosome to
Golgi retrieval [56]. The palmitoylation of Furin and
PC7 appears to control the precise localisation of these
proteins to particular lipid microdomains at the
plasma membrane [55]. Further investigation on the
acyl chain length added by ZDHHC5 to both Furin
and PC7 could be interesting as ZDHHC5 can use
lipids of differing chain lengths [57] which would all
confer different levels of hydrophobicity to these pro-
teins and presumably affect their partitioning.
ZDHHC5 also has a highly significant role in sens-
ing bacteria that invade the cell and the subsequent
immune response. ZDHHC5 palmitoylates a pair of
proteins Nucleotide oligomerisation domain (NOD)-
like receptor 1 (NOD1) and NOD2, which are both
essential for the sensing of bacteria present within the
cell [58]. These proteins are present on endosomal
membranes and the plasma membrane, and preventing
their palmitoylation causes them to lose their mem-
brane localisation. ZDHHC5 knockdown also causes a
similar phenotype and also prevents NOD1/2 from
localising to vacuoles containing pathogens [58].
ZDHHC5-mediated palmitoylation of NOD1/2
appears to be essential for the correct function of
NOD1/2 in this respect. Diseases caused by mutations
in NOD1/2, including Crohn’s disease, involve the
region of NOD1/2 that is palmitoylated, which could
implicate ZDHHC5 in these diseases also.
To identify potential drugs to fight the recent
COVID-19 pandemic, a large-scale AP-MS screen of
SARS-CoV-2 host–virus interactions was performed
[59]. Epitope-tagged versions of 26 of the 29 SARS-
CoV-2 viral proteins were expressed in HEK293 cells,
and host–protein interactors were identified using pull-
downs and mass spectrometry-based proteomics. Out
of 322 high confidence host–virus interactions, drugs
targeting 66 human protein were identified. Interest-
ingly, the viral Spike protein was found to interact
with just two proteins, ZDHHC5 and GOLGA7 [59].
The Spike protein of other coronaviruses is S-acylated
(by an unknown PAT) and that this modification is
very likely essential for viral fusion. S-acylation was
first discovered as a PTM in viruses over 40 years ago
[1]. Since this initial discovery, protein S-acylation has
emerged as an important regulatory mechanism for
several proteins in many viruses [60]. S-acylation of
the Spike protein in coronaviruses regulates host cell
fusion to allow infection to spread directly from cell to
cell [61] as well as regulating the major conformational
changes that the spike protein must undergo during
the process of fusion of cell and viral membranes [62].
To date, the enzymes responsible for the S-acylation of
just one viral protein has been identified [63]. Clearly,
the identification of the PAT or PATs responsible for
Spike protein palmitoylation is urgently required to
understand better how the virus manipulates the host
cell to replicate and complete its life cycle. The subcel-
lular location of spike protein palmitoylation is also of
interest given that palmitoylation occurs in the ER just
before the assembly of viral particles for other similar
viruses. It is possible that the co-localisation and there-
fore interaction of the Spike protein and ZDHHC5 is
an artefact of expression of the spike protein alone in
the absence of the other viral proteins. Whether palmi-
toylation of the Spike protein at the plasma membrane
or in endosomes by ZDHHC5 is possible or biologi-
cally relevant remains to be determined.
Regulation of ZDHHC5 by GOLGA7B
ZDHHC5 is a PAT which is generally localised to the
plasma membrane [24]. However, it can be trafficked
from the postsynaptic density to recycling endosomes,
through the AP2-mediated clathrin endocytic path-
way, [47]. However, until recently it was unknown if
other factors contribute to ZDHHC5 maintenance at
the plasma membrane in different cell types or if
palmitoylation of ZDHHC5 has any impact on its
subcellular localisation [29,30]. Woodley et al. [38]
recently identified and characterised the function of a
novel ZDHHC5 interactor and S-acylated protein
GOLG7B. GOLGA7B is closely related to GOLGA7,
which is a co-factor of the RAS PAT, DHHC9 [12]
and acts to stabilise the DHHC9-acyl chain intermedi-
ate [64].
ZDHHC5 S-acylates GOLGA7B but the interaction
between ZDHHC5 and GOLGA7B is not dependent
on the palmitoylation of GOLGA7B as the mutation
of these palmitoylation sites does not prevent the inter-
action [38]. However, preventing palmitoylation of the
three palmitoylation sites on the C-terminal tail of
ZDHHC5 abolishes the interaction between ZDHHC5
and GOLGA7B [38]. This could be due to a disruption
of the local protein structure that is formed when the
C-terminal tail is pinned to the membrane by palmi-
toylation.
Over-expression of ZDHHC5 generally causes a
mislocalisation of the protein leading to it being pre-
sent in other compartments of the cell as well as the
plasma membrane. This is a feature that has been
observed by others previously [65], but the reasons
for this were unknown. Recently, it was determined
that over-expression induced mislocalisation of
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ZDHHC5 could be reversed by co-expression of wild-
type GOLGA7B, but not by co-expression of the
palmitoylation-deficient mutant GOLGA7B [38]. Fur-
thermore, siRNA-mediated depletion of GOLGA7B
causes ZDHHC5 to be mislocalised similarly, and this
is not rescued by the expression of the closely related
protein GOLGA7 [38]. This suggests that when
ZDHHC5 is over-expressed, it is the lack of GOL-
GA7B that causes the mislocalisation phenotype and
that this effect on ZDHHC5 is likely to be specific to
GOLGA7B and not a more general feature of the
Golgin protein family [66]. The C-terminal S-acylation
mutant ZDHHC5 is unaffected by either wild-type or
mutant GOLGA7B expression and is also exclusively
present at the plasma membrane even when over-ex-
pressed [38].
These results allow several conclusions to be drawn.
Firstly, plasma membrane localisation of ZDHHC5 is
stabilised by GOLGA7B, but only when GOLGA7B is
palmitoylated. Secondly, if palmitoylation of GOL-
GA7B is prevented, then ZDHHC5 is internalised
(Fig. 3) and appears to be present throughout the cell.
It is also apparent that the level of GOLGA7B in the
cell is important in ensuring that ZDHHC5 is present
at the plasma membrane, as depletion of GOLGA7B
causes endogenous ZDHHC5 to be mislocalised to
internal membranes away from the plasma membrane
and over-expression of ZDHHC5 without correspond-
ing over-expression of wild-type GOLGA7B leads to a
similar phenotype. This points to the presence of
palmitoylated GOLGA7B being a protective factor
from ZDHHC5 internalisation. Also, palmitoylation
of the C-terminal tail of ZDHHC5 is an important
factor in its interaction with GOLGA7B, but perhaps
more interestingly, it also plays a role in maintaining
the plasma membrane localisation of the protein.
When the C terminus of ZDHHC5 cannot be palmi-
toylated, trafficking of ZDHHC5 appears to be unaf-
fected as ZDHHC5 is at the plasma membrane.
However, this palmitoylation is likely to be important
in the endocytosis of ZDHHC5 as when the palmitoy-
lation sites are mutated ZDHHC5 is present at the
plasma membrane. This points to palmitoylation of
the ZDHHC5 C terminus as being an important regu-
lator or trigger for ZDHHC5 endocytosis.
Emerging mechanisms for ZDHHC5
regulation
A recent study has shown that ZDHHC5 has an
important, and previously unrecognised, role in a
novel form of cell death which is distinct from the
classical cell death pathways [67]. This work showed
that ZDHHC5 forms a complex with the DHHC9 co-
factor GOLGA7 at the plasma membrane, which then
leads to palmitoylation of unknown downstream pro-
teins to trigger cell death caused by a synthetic small
molecule CIL56 [67]. Cell death triggered by CIL56 is
dependent on the formation of a ZDHHC5-GOLGA7
complex, the catalytic activity of ZDHHC5, C-termi-
nal acylation of ZDHHC5 but not binding of clathrin
to ZDHHC5. This opens up the possibility that
ZDHHC5 and GOLGA7 form a functional PAT com-
plex similar to that of DHHC9 and GOLGA7,
although the work does not directly investigate this
possibility. A potentially more intriguing possibility is
that GOLGA7 is required to target ZDHHC5 to speci-
fic substrates, which require palmitoylation for CIL56-
mediated cell death.
There are some interesting similarities between the
interactions that occur between ZDHHC5 and
GOLGA7 [67] and GOLGA7B [38]. Both appear to
require the palmitoylation of the C-terminal tail of
ZDHHC5 to form stable complexes, as a C-terminal
acylation mutant is unable to form stable complexes
with either GOLGA7 or GOLGA7B, but neither
require ZDHHC5 to be active. This implicates a possi-
ble conformational change in the region immediately
Fig. 3. Proposed model of how palmitoylation of Golga7b regulates
plasma membrane localisation of ZDHHC5. (1) Binding to and S-
acylation of Golga7b by ZDHHC5 stabilises the complex at the
plasma membrane by preventing AP2 mediated endocytosis. (2) Loss
of Golga7b S-acylation allows binding of AP2 to ZDHHC5 and its
endocytosis.
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at the C-terminal of the 4th transmembrane domain of
ZDHHC5 when it is palmitoylated and that this
palmitoylation event allows this region of ZDHHC5 to
become a critical interaction interface for both
GOLGA7 and GOLGA7B.
These two studies reported differences in the impor-
tance of ZDHHC5 C-terminal palmitoylation for its
localisation at the plasma membrane. One found
ZDHHC5 to be localised to the plasma membrane
exclusively when palmitoylation of the C-terminal tail
was abolished [38] whereas the other found it to
accumulate in cytosolic puncta [67]. Another recent
study found that in neurons, the cell surface expression
of ZDHHC5 C-terminal palmitoylation mutant was
significantly increased compared with wild-type
ZDHHC5 due to a decrease in ZDHHC5 turnover [68]
supporting the former study [38]. A potential explana-
tion of these conflicting results may be due to differ-
ences in the cell types used.
Recent work focusing on the elucidation of fatty
acid uptake by CD36 revealed that CD36 is targeted
to the plasma membrane by S-acylation mediated by
DHHC4 and ZDHHC5 [69]. The activity of ZDHHC5
was found to be regulated by phosphorylation of tyro-
sine-91, which is located in the same intracellular loop
as the DHHC motif [70]. This site is phosphorylated
by the tyrosine kinase Lyn [70], a protein very highly
enriched in ZDHHC5 pulldowns analysed by mass
spectrometry [38]. Intriguingly, phosphorylation of
ZDHHC5 by Lyn at Y91 is induced by fatty acid (ole-
ate) treatment of cells, and this phosphorylation acts
to inhibit ZDHHC5 activity [70]. This inhibition of
ZDHHC5 allows the depalmitoylation of CD36 by
Acyl-protein thioesterase 1 (APT1), which initiates
CD36-mediated caveolar endocytosis of fatty acids
[70]. In this way, palmitoylated CD36 captures fatty
acids at the plasma membrane, and its depalmitoyla-
tion triggers its endocytosis and therefore the uptake
of captured fatty acids (Fig. 4). It remains to be deter-
mined how exactly phosphorylation of ZDHHC5 at
Y91 regulates its enzymatic activity, but phosphoryla-
tion may cause a conformational change in the cytoso-
lic loop that contains the DHHC motif (Fig. 1).
Detailed structural studies should resolve whether this
is a likely mechanism or not.
Conclusions
A model of ZDHHC5 regulation is emerging that uti-
lises phosphorylation by tyrosine kinases to regulate
its activity and localisation; in the case of Y91 by
directly regulating enzyme activity and for Y533 by
regulating its cell surface expression by blocking its
endocytosis. ZDHHC5 cell surface expression is also
regulated by S-acylation of the C terminus of
ZDHHC5 and by binding to GOLGA7 or GOL-
GA7B. Whilst some of these mechanisms of ZDHHC5
regulation have been shown to occur in different cell
types, it is not yet clear which are employed univer-
sally or in a cell type-specific manner. More work is
required to refine our current understanding of
ZDHHC5 regulation in a wider variety of cell and tis-
sue types, and the extensive PTM of the sizeable C-ter-
minal domain remains relatively unexplored.
Fig. 4. Regulation of fatty acid uptake by ZDHHC5-mediated S-
acylation of CD36. (1) In basal conditions CD36 is S-acylated by
ZDHHC5 in caveolae. (2) Binding of fatty acids to CD36 leads to
activation of LYN and phosphorylation of ZDHHC5 and its
inactivation. (3) De-acylation of CD36 by APT1 leads to caveolar
endocytosis and fatty acid uptake.
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